The NRTO project is pleased to announce its active participation in the upcoming SCCOHT-SMARCA4 Symposium 2025, taking place from May 21st to 23rd at the Faculty Club, McGill University, in Montreal, Canada. This event marks the second meeting of the International SCCOHT Consortium and serves as a key international platform for scientific and clinical exchange around small cell carcinoma of the ovary, hypercalcemic type (SCCOHT) and SMARCA4-related alterations.
The symposium will bring together leading international experts, basic and clinical researchers, patient advocates, and rare cancer foundations to address both molecular and therapeutic challenges of SCCOHT. Esteemed institutions such as McGill University, University of British Columbia, University Health Network, Cincinnati Children’s Hospital, Centre Léon Bérard, Gustave Roussy, Royal Marsden Hospital, and Merck will be among the contributors.
NRTO will be represented by members of its research team and collaborators, reinforcing its dedication to international cooperation on rare gynecological tumors. This presence highlights NRTO’s commitment to cutting-edge science, translational research, and the development of new therapeutic avenues for ultra-rare diseases.
Key sessions at the symposium will include:
- Patients, advocacy, and tumor registries
- Basic science of SCCOHT and SMARCA4
- Clinical challenges and novel therapeutic approaches
- Collaborative opportunities and consensus building
In addition to the scientific sessions, the symposium will offer multiple networking opportunities and interdisciplinary discussions, essential to advancing integrated approaches to rare cancer research.
For more information about the event or to join via livestream, visit:
SCCOHT-SMARCA4 Symposium 2025 – Livestream
NRTO is proud to join this global initiative and remains committed to advancing science for the benefit of those affected by rare oncological diseases.
